The use of CpG DNA as a mucosal vaccine adjuvant

Current Opinion in Investigational Drugs

Volumn 2, Issue 1, 2001, Pages 35-39

  McCluskie, M J ^a   Weeratna, R D ^a   Payette, P J ^a   Davis, H L ^a  

^a Coley Pharmaceutical Canada ^*  (Canada)

Author keywords

Adjuvant; CpG; Immunostimulatory; Mucosal; Oligodeoxynucleotides; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ANTIGEN; BCG VACCINE; BETA GALACTOSIDASE; CHOLERA TOXIN; CYTOKINE; DNA VACCINE; ESCHERICHIA COLI ENTEROTOXIN; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HERPES SIMPLEX VACCINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INFLUENZA VACCINE; INTERLEUKIN 12; KEYHOLE LIMPET HEMOCYANIN; MITOGEN ACTIVATED PROTEIN KINASE; OLIGODEOXYNUCLEOTIDE DERIVATIVE; REACTIVE OXYGEN METABOLITE; TETANUS TOXOID; TUMOR NECROSIS FACTOR; VIRUS PROTEIN;

ADJUVANT THERAPY; ALLERGIC CONJUNCTIVITIS; ASTHMA; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; IMMUNOSTIMULATION; MEASLES VACCINATION; NONHUMAN; REVIEW; SEXUAL TRANSMISSION; T LYMPHOCYTE; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ASTHMA; HUMANS; IMMUNITY, MUCOSAL; OLIGODEOXYRIBONUCLEOTIDES; VACCINES;

EID: 0035148183     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. The mucosal immune system: From fundamental concepts to vaccine development
2. Recent advances in vaccine adjuvants for systemic and mucosal administration
3. Modulation of immune responses following antigen administration by mucosal route
4. Advances in vaccine adjuvants
5. Use of CpG DNA for enhancing specific immune responses
6. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen
7. CpG DNA induces stronger immune responses with less toxicity than other adjuvants
8. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans
9. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo
10. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys
11. CpG ODN is safe and highly effective in humans as adjuvant to HBV vaccine: Preliminary results of phase i trial with CpG ODN 7909
12. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice
13. CpG DNA as mucosal adjuvant
14. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants
15. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution
16. CpG DNA is an effective oral adjuvant to protein antigens in mice
17. Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes
18. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus
19. Immunostimulatory DNA is a potent mucosal adjuvant
20. Immunostimulatory sequence oligodeoxynucleotide: A novel mucosal adjuvant
21. Immunostimulatory-sequence DNA is an effective mucosal adjuvant
22. CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M tuberculosis
23. Antipeptide antibody responses following intranasal immunization: Effectiveness of mucosal adjuvants
24. Intranasal immunization with CpG ODN dramatically increases IgA and protection against HSV-2 in the genital tract
25. CpG motifs in bacterial DNA trigger direct B-cell activation
26. Mechanism of action of CpG DNA
27. CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-Myc and Bcl-xL
28. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species
29. CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of IκBα and IκBβ and sustained activation of nuclear factor-κ B/c-Rel
30. CpG DNA rescues B cells from apoptosis by activating NFκB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway
31. Macrophages ingest and are activated by bacterial DNA
32. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA
33. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation
34. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry
35. Immunostimulatory DNA pre-priming: A novel approach for prolonged Th1-biased immunity
36. Induction of mucosal immune responses in the human genital tract
37. Bacterial toxins as mucosal adjuvants
38. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming
39. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice
40. Oral but not parenteral interleukin (IL)-12 redirects T-helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses
41. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin
42. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines
43. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates
44. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ
45. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma
46. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice
47. Regulation of T-helper type 2 cell and airway eosinophilia by transmucosal coadministration of antigen and oligodeoxynucleotides containing CpG motifs
48. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides
49. Oligodeoxynucleotides containing CpG motifs modulate the allergic TH2 response of BALB/c mice to Bet v 1, the major birch pollen allergen
50. CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma
51. Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis
52. Species differences in the physical and transport properties of airway secretions
53. Immunobiology of the tonsils and adenoids
54. The role of nasopharyngeal lymphoid tissue
55. Nasal lymphoid tissue (NALT) as a mucosal immune inductive site
56. IL-12 is an effective adjuvant for induction of mucosal immunity
57. Novel strategies using DNA for the induction of mucosal immunity